Beta-containing COVID-19 booster vaccine found to cross-neutralize

$ 26.99

4.9 (608) In stock

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Sanofi-GSK COVID-19 booster could compete against updated Moderna and Pfizer offerings - Drug Discovery and Development

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Role of the humoral immune response during COVID-19: guilty or not guilty? - Mucosal Immunology

Vaccines, Free Full-Text

Frontiers Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Moderna Says Studies Show Its Vaccine Is Effective Against The Delta Variant

Current vaccines teach T cells to fight Omicron

JCM, Free Full-Text

Neutralization of SARS-CoV-2 variants by NVX-CoV2373 vaccinee plasma.

Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern, Journal of Biomedical Science

Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants

A Future-Proof Coronavirus Vaccine - McGill University

Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2